Double blind placebo controlled dose ranging study of the efficacy and safety of SSR149744C [Celivarone] 300 or 600mg for the conversion of atrial fibrillation/flutter.

Trial Profile

Double blind placebo controlled dose ranging study of the efficacy and safety of SSR149744C [Celivarone] 300 or 600mg for the conversion of atrial fibrillation/flutter.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 May 2012

At a glance

  • Drugs Celivarone (Primary)
  • Indications Atrial fibrillation; Atrial flutter
  • Focus Therapeutic Use
  • Acronyms CORYFEE
  • Most Recent Events

    • 22 Dec 2008 Actual end date (Apr 2006) added as reported by ClinicalTrials.gov.
    • 22 Dec 2008 Planned number of patients changed from 141 to 150 as reported by ClinicalTrials.gov.
    • 05 Oct 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top